CDX1 is a transcription factor that plays a key role in intestinal development and differentiation. However, the downstream targets of CDX1 are less well defined than those of its close homologue, CDX2. We report here the identification of downstream targets of CDX1 using microarray gene-expression analysis and other approaches. Keratin 20 (KRT20), a member of the intermediate filament and a well-known marker of intestinal differentiation, was initially identified as one of the genes likely to be directly regulated by CDX1. CDX1 and KRT20 mRNA expression were significantly correlated in a panel of 38 colorectal cancer cell lines. Deletion and mutation analysis of the KRT20 promoter showed that the minimum regulatory region for the control of KRT20 expression by CDX1 is within 246 bp upstream of the KRT20 transcription start site. ChIP analysis confirmed that CDX1 binds to the predicted CDX elements in this region of the KRT20 promoter in vivo. In addition, immunohistochemistry showed expression of CDX1 parallels that of KRT20 in the normal crypt, which further supports their close relationship. In summary, our observations strongly imply that KRT20 is directly regulated by CDX1, and therefore suggest a role for CDX1 in maintaining differentiation in intestinal epithelial cells. Because a key feature of the development of a cancer is an unbalanced program of proliferation and differentiation, dysregulation of CDX1 may be an advantage for the development of a colorectal carcinoma. This could, therefore, explain the relatively frequent down regulation of CDX1 in colorectal carcinomas by hypermethylation.
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colorectal cancer ͉ epithelial ͉ cell lines ͉ methylation ͉ cancer stem cells M embers of the keratin family provide structural support for the cell. They are also involved in apoptosis and protect cells from stress (1) . Mutations of some keratins lead to genetic diseases, for example, of the skin and the liver (2) (3) (4) . Keratin 20 (KRT20), a member of the keratin family, has been cloned and classified as a type-I keratin with a highly conserved amino acid sequence (5) . It is mainly expressed in the cytoplasm of epithelial cells in the small and large intestine and in Merkel cells of the skin (5) . As KRT20 is expressed in the epithelial cells of the crypt, it has been widely studied as a marker of differentiation in normal epithelium and colorectal cancer (CRC) samples (6) (7) (8) (9) . Previous studies have suggested that KRT20 is phosphorylated in association with mucin secretion and filament organization (10, 11) . Transgenic mice with mutations at a conserved Arg to His site (R80H) show collapse of intermediate filaments.
Despite its clearly important functions in the intestine, little is known about the regulation of KRT20.
CDX1 is a homeobox transcription factor that is important for intestinal development and is specifically expressed in the small and large intestine in both mice and humans (12) (13) (14) (15) . CDX1 plays a role in intestinal epithelial cell differentiation (16) and is down-regulated in a number of CRC-derived cell lines as well as in patient samples (17) (18) (19) . This suggests that absence of CDX1 expression is an advantage for the development of colorectal carcinomas. However, there have so far been only limited studies of the downstream targets of CDX1 (20) (21) (22) . To examine further the functional role of CDX1, we have investigated its downstream targets using microarray gene-expression analysis and other approaches. Our results show that CDX1 directly regulates KRT20, which further supports the role of CDX1 in maintaining differentiation in the intestinal crypt and therefore supports an important role for CDX1 in colorectal carcinogenesis.
Results

Identification of CDX1 Downstream Targets by Microarray Analysis.
The CDX1 cDNA transfected cell line, HCT116-CDX1, showed a substantial increase in CDX1 message and protein expression as compared to its CDX1-negative parent, HCT116, while the siRNA transfected line LS174T-siRNA showed a substantial reduction in message and an 85% reduction in CDX1 protein expression relative to its CDX1-positive parent, LS174T. Protein expression was checked by Western blot [supporting information (SI) Fig. S1 ]. The specificity of the CDX1 knock down was confirmed by the fact that there was no reduction in CDX2 protein expression in the siRNA transfected LS174T cell line as compared to the vector control. RNA from both pairs of stably transfected cell lines was submitted to microarray geneexpression analysis.
The expression of 105 genes was up-regulated at least 1.5-fold in HCT116-CDX1 as compared to its control, but unchanged in LS174T-siRNA in comparison with its control. The expression of 181 genes was down-regulated at least 1.5-fold in the LS174T-siRNA but unchanged in HCT116-CDX1. No genes were found that were down-regulated in HCT116-CDX1 and up-regulated in LS174T-siRNA. However, there were 5 genes that were upregulated in HCT116-CDX1 and down-regulated in the LS174T-siRNA (Table 1) . These genes were therefore considered to be prime candidates for direct regulation by CDX1.
The expression pattern of these 5 candidate genes in HCT116-CDX1, as determined by quantitative PCR (qPCR), gave results for IL 18, dipeptidylpeptidase 4 (DPP4), and KRT20 that were consistent with the microarray data (Fig. 1A) . IL 18 is a regulator of IFN ␥ and Fas ligand-dependent cytotoxicity by T lymphocytes (23) . It is expressed in intestinal epithelial cells (24) and has been suggested to play a role in the maintenance of intraepithelial lymphocytes (25) and in antitumor immunity (23) . DPP4 (also known as CD26) has a role in activation of T cells (26) . Expression of DPP4 has been shown to correlate closely with that of other markers of intestinal epithelial differentiation, such as brush border formation and some related enzyme activities. KRT20 is a well-known marker of intestinal epithelium differentiation.
Among the 5 genes tested on HCT116-CDX1, only the qPCR results for KRT20 were consistent with the microarray data from LS174T-siRNA (Fig. 1B) . Given the strong association of KRT20 expression with intestinal epithelial differentiation, we therefore decided to focus on characterizing the relationship between CDX1 and KRT20.
Analysis of CDX1, KRT20, and A33 RNA Expression in CRC Cell Lines.
Our previous work has shown that about 20% of CRC cell lines have low or absent CDX1 mRNA expression because of hypermethylation of the CDX1 promoter region (19) . In this study we examined the expression of CDX1 in an additional 32 CRC cell lines, as well as in 6 that had been studied previously, using semiquantitative RT-PCR. In agreement with the earlier work, we found that 10 out of the 38 cell lines had low or absent expression of CDX1 mRNA, and that was regulated by promoter hypermethylation, as demonstrated by methylation-specific PCR (Table S1 ). Combining these results with our previous data (19), 12 out of 68 of the CRC cell lines lack CDX1 expression because of hypermethylation, and 1 lacking expression is hemimethylated (Table S2) .
The mRNA expression of the transmembrane protein A33, which has been shown to be a direct target of CDX1 (21), was also checked in our panel of cell lines. The results (see Tables S1,  S3 , and S4) show that CDX1 and A33 expression are highly correlated (P Ͻ 0.01). The expression of CDX1 and KRT20 was also highly correlated (P Ͻ 0.01). The homeobox gene CDX2, a close relative of CDX1 with apparently related functions (27) , was expressed at the mRNA level in most of the CRC cell lines and showed no obvious relationship with expression of either KRT20 or A33.
CDX1 Regulates KRT20 by 2 Putative Binding Sites in the KRT20
Promoter. The promoter region sequence of KRT20 was obtained from the University of California, Santa Cruz Genome Bioinformatics site (http://www.genome.ucsc.edu). It contains 6 putative CDX consensus binding sites based on predictions by the TRANSFAC software and published studies (21, 28) . CDX1 and CDX2 binding sites cannot be distinguished. There is 68% homology between human and mouse KRT20 in the 500-bp upstream of the 5Ј UTR (Fig. 2 ). This region is therefore presumed to be the minimal promoter, as the homology of the region further upstream drops to below 50%. Deletions from 500-bp to 2-kb upstream of the transcription start site do not show a significant reduction in luciferase activity when tested in a reporter assay (data not shown). Primers were therefore designed to amplify 5 fragments (see Fig. 2 , FA-FE) with different combinations of the predicted 6 CDX binding sites found in the 500-bp upstream region of KRT20. These fragments were cloned into the pGL3 luciferase vector for transient transfection assays (Fig. 3A) . Three cell lines were chosen for these assays: (i) RKO, which was fully methylated and expressed neither CDX1 nor KRT20; (ii) LOVO, which was partially methylated and expressed both CDX1 and KRT20 at low levels; and (iii) LS174T, which was umethylated and expressed both CDX1 and KRT20 at high levels. Deletion of the region between -501 and -246 bp (i.e., FB-FE) did not significantly reduce the KRT20 promoter activity as measured by the relative luciferase activity, suggesting that the CDX putative sites in this region do not contribute significantly to the regulation of KRT20. In contrast, there was a significant reduction in KRT20 luciferase activity between FB and FA in all 3 cell lines, although more markedly in LOVO and LS174T (Fig.  3B ). This suggests that the 2 CDX putative binding sites located within the region 246-bp upstream of the transcription start site may be the major contributors to the regulation of KRT20 transcription by CDX1. KRT20 luciferase activity remains low in all cases in the CDX1-and KRT20-negative cell line RKO.
To further confirm the role of the 2 CDX binding sites within the -246-bp region in the regulation of KRT20 transcriptional activity, FA and FB fragments were cotransfected with either pCMV/CDX1 cDNA or pRC/CMV vector control into the same 3 cell lines. As shown in Fig. 3C , there is no significant increase in luciferase activity in any of the 3 cell lines when FA is cotransfected with CDX1, as compared to the vector control. However, cotransfection of CDX1 and FB significantly induces KRT20 luciferase activity even in RKO, consistent with the assumption that activity is determined by the binding of CDX1 to the putative CDX binding sites in fragment FB.
As an additional test of the relevance of the 2 putative CDX binding sites in fragment FB, we studied the effect of mutation of one or both of these sites on the induced luciferase activity. Mutations in either site M1 or M2 reduced the luciferase activity by 30 to 40% in comparison with the intact FB, and this was further reduced when both sites were mutated (Fig. 3D) . The decrease in promoter activity when sites M1 and M2 are both mutated adds to the evidence that both these CDX binding sites are required for maximum induction of KRT20 expression by CDX1.
Characterization of an Anti-CDX1 Monoclonal Antibody. To investigate the expression of the CDX1 protein and to obtain further evidence for KRT20 as a downstream target of CDX1 using a ChIP assay, we developed a monoclonal antibody (mAb) raised against a peptide corresponding to an N-terminal amino acid sequence of CDX1. The specificity of the antibody was confirmed by the fact that only the N-terminal peptide blocked the CDX1 mAb activity on an immunoblot of a lysate from HCT116-CDX1 (Fig. 4A) . The anti-CDX1 antibody specificity was further established by the complete concordance between its reactivity on immunoblots and CDX1 mRNA expression from 4 CDX1-positive and 4 negative cell lines (Fig. 4B) . In all cases, the positive immunoblots identified a single band of about 32 kDa, which corresponds approximately to the expected size of the CDX1 protein. The antibody also detected the expected band in LS174T-Vec, but not in the LS174T-siRNA cells (Fig. 4C) . The KRT20 protein is, furthermore, only expressed when the CDX1 protein is expressed.
We further confirmed the results by immunohistochemistry. As shown in Fig. 4D , the anti-CDX1 mAb readily shows strong CDX1 staining in LS174T-Vec and HCT116-CDX1, but essentially gave no staining in the CDX1-negative LS174T-siRNA and HCT116-Vec.
CDX1 Regulates KRT20 Directly in Vivo. In vivo binding of CDX1 to the KRT20 promoter was studied using a ChIP assay both with our anti-CDX1 mAb and with a commercially available CDX1 polyclonal antibody (Abcam). Normal mouse IgG antibody was used as a negative control. DNA isolated from immunoprecipitated chromatin from the HT55 cell line (another unmethylated CDX1-expressing line) was amplified, as described in Materials and Methods, by primers flanking the 2 putative CDX binding sites in fragment B. Fig. 5 shows that the resulting DNA pulled down by both the anti-CDX1 antibodies contained the sequences flanking the 2 putative CDX binding sites. This demonstrates that CDX1 binds the 2 sites within the first 219 bp of the KRT20 promoter in fragment B, and supports strongly the conclusion that KRT20 mRNA expression is directly regulated by CDX1.
Parallel Expression of CDX1 and KRT20 in Normal Crypt. The expression of the CDX1 and KRT20 proteins in the colonic normal crypt was investigated by immunohistochemistry using both the anti-CDX1 polyclonal antibody and an anti-KRT20 monoclonal antibody. CDX1 expression appears to increase from near the bottom to the top of the crypt (Fig. 6A) and largely parallels the expression of KRT20 (Fig. 6B) . The CDX1 mAb also shows increased staining from the bottom to the top of the crypt. However, in this case, there is also staining in the cytoplasm of the muscularis mucosae because of cross-reaction with a different protein that is not expressed in the epithelial cells (data not shown). As has already been shown in a study by Moll et al. (5) , KRT20 is absent from the bottom of the crypt and gradually increases to its highest level of expression in epithelial cells at the top of the crypt. The CDX1 staining is nuclear, while the KRT20 expression is cytoplasmic. The approximate colocalisation of the CDX1 and KRT20 expression is consistent with regulation of KRT20 by CDX1.
Discussion
Using microarray gene-expression analysis on paired cell lines that do and do not express the homeobox gene CDX1, we identified KRT20, a well-known marker of differentiated intestinal epithelium, as a candidate for direct regulation by CDX1. This is supported by the strong relationship between CDX1 and KRT20 expression in a panel of CRC-derived cell lines. We also identified 2 key CDX binding sites within 246-bp upstream of the start site in the KRT20 promoter as the main contributors to the regulation of KRT20 expression by CDX1. Using a recently derived anti-CDX1 monoclonal antibody, we have confirmed that CDX1 binds to this region of the CDX1 promoter in vivo. Finally, immunohistochemical analysis of normal colorectal epithelium shows that both CDX1 and KRT20 tend to be colocalized in the upper-differentiated part of the crypt, with CDX1 in the nucleus and KRT20 in the cytoplasm.
CDX1 also seems to play a key role in the control of the expression of the transmembrane protein, A33, which is almost uniquely associated with intestinal epithelium (21, 29, 30) . Other published evidence suggests that ectopic expression of CDX1 in an undifferentiated rat cell line results in differentiated phenotypes with columnar epithelial features, together with induction of differentiation markers, such as villin and aminopeptidase N (16). It seems likely that the expression of other markers of intestinal epithelial differentiation, such as villin, MUC2, and sucrase isomaltase, may also be regulated by CDX1. The overall data are consistent with the idea that CDX1 expression is a key switch for intestinal epithelial differentiation, as suggested by Wong et al. (29) with respect to the development of intestinal metaplasia in Barrett's oesophagus, and presumably also in gastric mucosa (31) , where intestinal metaplasia is assumed often to be a precursor to the development of gastric carcinomas. The differential expression of CDX1 appears to be controlled by promoter methylation (19, 29) .
A number of intestine-specific genes, including lactasephlorizin hydrolase, calbindin-D9K, carbonic anhydrase, gutenriched Kruppel-like factor, MUC2, sucrase isomaltase, and liver intestine (L1)-cadherin have been characterized as being regulated by CDX2 (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . The relationship of these downstream targets regulated by CDX1 and CDX2 is not clear. Our data suggest that CDX1 is the proximal determinant of intestinal differentiation, but it is probable that its activity depends on cooperation with CDX2. Recent work by Bonhomme et al. (42) indicates that intestinal differentiation in a mouse knock out for CDX1 proceeds more or less normally. This suggests that CDX2 may substitute for CDX1 in its absence, but not vice versa, as CDX2 knock outs are lethal. Our results, showing CDX2 mRNA expression in most of the CRC cell lines that we studied, are not in agreement with claimed evidence for consistent downregulation of CDX2 (39-41) in CRC.
The initial microarray analysis suggested that IL 18 and DPP4 may also be directly regulated by CDX1. These 2 genes are related to T cell activation, suggesting CDX1 may also have a role in inflammatory and immune responses in the gut.
We have previously shown that the mRNA expression of CDX1 in partially methylated cell lines could be increased by 5-aza-2Ј deoxycytidine treatment and that ''postconfluent'' growth of these partially methylated cell lines, such as LOVO, led to an increase in CDX1 expression that was correlated with a decrease in methylation of a key region in the CDX1 promoter (19) . It is now widely accepted that cancer stem cells are the driving cells of a cancer, which will also contain the differentiated cells derived from them (43) . A cancer therefore, to some extent but in a disordered and dysregulated manner, recapitulates the process that occurs in the normal tissue and the same is true in cell lines derived from cancers and grown in vitro. The data on the CDX1 partially methylated cell lines therefore suggests that postconfluent growth increases the proportion of differentiated cells as compared to cancer stem cells in these cultures. This is accompanied by a reduction in overall promoter methylation of CDX1 associated with the triggering of differentiation in the differentiated cell component in the cell culture.
As suggested by Wong et al. (19) , selection for reduced expression of CDX1 by methylation in colorectal cancers (17) (18) (19) is likely to be associated with a reduced capacity of the cancer stem cells to differentiate and so to contribute to an increased rate of growth. Studying the patterns of expression of CDX1 and its downstream-regulated differentiation markers, such as KRT20, should therefore enable better characterization of cancer stem cells both in CRC cell lines and in primary CRCs.
Materials and Methods
Detailed materials and methods can be found in the SI Text.
Cell Lines and Cell Culture. CaCO2, CCK-81, COLO320DM, DLD1, HCT116, HT29, LOVO, LS123, LS174T, NCI H548, RCM1, SKCO1, SW48, SW837, and SW1116 were cultured in E4 medium [Cancer Research U.K. (CRUK) Cell Services]. COLO678, LS513, NCI-H716, RKO, SW1222, and SW1417 were cultured in RPMI1640 medium (CRUK). The rest of the cell lines were grown in Iscoves medium (Invitrogen). All of the above media were supplemented with 10% FCS (Autogen Bioclear), 1% glutamine, and 1% Penicillin-streptomycin (Invitrogen). Cell lines were kept in a 10% CO 2 incubator except those grown in RPMI1640 medium, which were kept in a 5% CO 2 incubator. Cells were grown to 50 to 80% confluence before next passage or further experiments (19) .
Stable Transfection and Microarray. The CDX1 nonexpressing CRC cell line HCT116 was stably transfected with either CDX1 cDNA in the pRC/CMV expression vector (HCT116-CDX1) or with vector control (HCT116-Vec), followed by Geneticin (G418) selection to generate stable clones. The strongest CDX1 expressing clone was then chosen for further study. The CDX1-expressing CRC cell line LS174T was similarly transfected with either a pSilencer vector (Ambion) containing a short sequence of CDX1 siRNA (LS174T-siRNA), or a pSilencer vector containing a scrambled siRNA sequence as a control (LS174T-vec), followed by G418 selection to generate stable clones. The clone that had the greatest reduction in CDX1 expression was, again, selected for further study. The 63-bp length oligonucleotide (Top strand: 5Ј-GATCCGACTCGGAC-CAAGGACAAGTTCAAGAGACTTGTCCTTGGTCCGAGTCTTTTTTGGAAA-3Ј and bottom strand: 5Ј-AGCTTTTCCAAAAAAGACTCGGACCAAGGACAAGTCTCTT-GAACTTGTCCTTGGTCCGAGTCG-3Ј) of CDX1 siRNA was designed using Ambion online guidelines. The transfected clones were selected in 1-mg/ml G418 (Invitrogen). Total RNA was extracted by using the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Ten micrograms of RNA of each sample were sent to the Molecular Biology Core Facility of the Paterson Institute for Cancer Research for gene-expression microarray analysis using the Human genome U133 plus 2.0 chips following the manufacturer's instructions (Affymetrix). Gene expression data were normalized using the RMA (Robust Multichip Analysis) algorithm. A fold change of 1.5 with 95% significance level was selected as the threshold for the comparison between the paired cell lines.
RT-PCR. RT-PCR was done using standard procedures, as described in the SI Text. Normalization was carried out as previously described (44) .
Plasmid Constructs and Site-Directed Mutagenesis. DNA fragments of the human KRT20 promoter were cloned from cell line HDC8 using the primers given in Tables S5 and S6 (see also Fig. 2 ). Detailed cloning procedures are described in the SI Text. Full-length CDX1 cDNA was cloned as a HindIII-NotI fragment in a pRC/CMV expression vector and is referred to as pRC/CMV-CDX1 (a kind gift from Dr. Jaleh Malakooti). All constructs were prepared using the Endo-free Plasmid Maxi Kit (Qiagen) and verified by DNA sequencing before further study.
Transient Transfection and Luciferase-Reporter Assay. Cells were trypsinised, counted, and plated at a density of 1 ϫ 10 6 cells per well in 6-well plates (Corning) 1 day before transfection. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Transfection efficiencies were normalised to Renilla luciferase activity as described in the SI Text.
Production of Anti-CDX1 Monoclonal Antibody. The CDX1 anti-human mAb was produced against the human CDX1 peptide ANYGPPAPPPAPPQYPDFSS (referred to as N-term peptide) synthesized by the CRUK Peptide Synthesis Laboratory and used to immunise BALB/c mice. Monoclonal antibodies were raised in the CRUK Tumor Pathology Group laboratory, Oxford, using conventional hybridoma production methods. The mAb was purified from the supernatant and concentrated using the Montage antibody purification kit (Millipore) following the manufacturer's instructions.
Immunoblotting and Peptide Blocking. Total protein lysate was analyzed using a standard immunoblot protocol. The antibodies and dilutions used were as follows: anti-CDX1 mAb (0.1 g/ml), anti-KRT20 mAb (Dako) (1:4,000), antibeta tubulin mAb (Sigma) (1:5,000), and rabbit anti-mouse secondary antibodies conjugated with HRP (1:10,000).
Chromatin Immunoprecipitation. ChIP was performed using the EZ ChIP Chromatin Immunoprecipitation Kit (Millipore) according to the manufacturer's instructions.
Immunohistochemistry. Immunohistochemistry was performed following standard procedures. The concentrations of antibody used for immunohistochemistry were: anti-CDX1 pAb (Abcam 1: 500) and anti-KRT20 mAb (Dako 1:200).
Statistical Analysis. All data are shown as mean Ϯ SEM. For pairwise analysis, Student's t test was used. For all statistical comparisons, P Ͻ 0.001 was denoted as ***, P Ͻ 0.01 as **, and P Ͻ 0.05 as *.
